Greenwich LifeSciences, Inc.: dividend

GLSINASDAQHealthcare · Pharmaceutical Preparations

Price

$19.25

November 20, 2026Market cap $283M

What Ploutos Investor adds for Greenwich LifeSciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.

Greenwich LifeSciences pays no dividend

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 10.6% in a year.

All dividend stocks

The full analysis

What do Greenwich LifeSciences's filings show?

The dividend is one part of Greenwich LifeSciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about GLSI's dividend

Didn't find what you were looking for?

Ask us
Does GLSI pay a dividend?

It paid no dividend in any of the fiscal years we hold, nor over the last 12 months. Nor does it buy back shares: its share count rose 10.6% in a year.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.